Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,441
- Drugs tracked
- 4,077
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
BI 1015550, Placebo matching nerandomilast (BI 1015550)
Boehringer Ingelheim International GmbH
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)
1 trial -
A study in healthy men to test how bosentan influences the amount of nerandomilast in the blood
Boehringer Ingelheim International GmbH
Healthy volunteer trial
1 trial -
A study in healthy men to test whether carbamazepine influences the amount of nerandomilast in the blood
Boehringer Ingelheim International GmbH
Healthy volunteer trial
1 trial -
BI 1015550, NERANDOMILAST
Boehringer Ingelheim International GmbH
Healthy volunteer trial
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources